Acute kidney Injury due to Alectinib, an Anaplastic Lymphoma Kinase inhibitor. Issue 1 (February 2021)

• Record Type: Journal Article
• Authors: Ng, Chin Lin; Abdalla, Alaeldin; Galambosi, Greta; Cuffe, Sinead; Doyle, Brendan; Griffin, Brenda; Sexton, Donal J
• Is Part Of: Journal of onco-nephrology. Volume 5:Issue 1(2021)
• Page Start: 18
• Page End: 22
• Publication Date: 2021-02
• Subjects: Alectinib -- kidney-injury -- anaplastic lymphoma kinase; Nephrology -- Periodicals; Kidneys -- Cancer -- Periodicals; Kidneys -- Tumors -- Periodicals; 616.61
• DOI: 10.1177/2399369321989718
• Languages: English
• ISSNs: 2399-3693

Abstract

Introduction: The array of unintended effects of targeted oncological treatments is still being elucidated. Cognizance of these effects is important since they allow early identification and intervention. Methods: We report a case of progressive reduction in kidney function following the introduction of the oral second generation Anaplastic Lymphoma Kinase (ALK) Inhibitor: Alectinib for the treatment of metastatic non-small cell carcinoma of the lung (NSCLC). Kidney biopsy findings suggested that the predominant manifestation was acute tubular injury, which resolved with cessation of Alectinib therapy and did not recur with the introduction of the third generation ALK inhibitor Lorlatinib. Conclusions: This case report adds to the Onco-Nephrology literature in relation to the potential nephrotoxic effects of ALK inhibitors.